What lab tests are used to diagnose Ehlers-Danlos syndrome?

Laboratory Testing for Ehlers-Danlos Syndrome

Most EDS subtypes require genetic testing for definitive diagnosis, but hypermobile EDS (hEDS)—the most common form—is diagnosed purely clinically without any available genetic test. 1, 2, 3

Primary Diagnostic Approach by EDS Subtype

Vascular EDS (Type IV) - Most Critical to Identify

COL3A1 gene mutation testing is the definitive diagnostic test for vascular EDS and should be performed urgently when this life-threatening subtype is suspected. 4, 1, 5

• Baseline serum tryptase level should be obtained, as elevated levels are commonly observed in myeloproliferative variants and can help distinguish vascular complications 6, 1
• Vitamin B12 level is characteristically elevated in myeloproliferative variants of EDS with arteriopathy 6
• Fibroblast culture demonstrating structurally abnormal collagen type III provides supportive evidence but requires invasive skin biopsy 1, 7

Classical EDS (Types I and II)

• COL5A1 or COL5A2 gene mutation testing provides molecular confirmation 1
• Gene panel testing covering multiple EDS-associated genes is more efficient than single-gene sequencing 8

Hypermobile EDS (hEDS) - 80-90% of All EDS Cases

No genetic test exists for hEDS; diagnosis relies entirely on clinical criteria including Beighton score ≥5/9 for joint hypermobility. 6, 1, 2

• Celiac disease serological testing should be performed earlier in hEDS patients presenting with any GI symptoms 1
• Baseline serum tryptase level if symptoms suggest mast cell activation syndrome (flushing, urticaria, wheezing, multisystem symptoms) 6, 1
• Postural vital signs with heart rate increase ≥30 beats/min within 10 minutes of standing screens for POTS, which affects many hEDS patients 6, 1

Comprehensive Gene Panel Testing Strategy

When EDS is suspected but subtype is unclear, multi-gene panel testing (covering COL3A1, COL5A1, COL5A2, TGFBR1, TGFBR2, PLOD1, and other arteriopathy genes) is the most efficient diagnostic approach. 4, 8

• Gene panels identified molecular diagnoses in 75% of patients meeting clinical EDS criteria and 28% of patients with overlapping features 8
• Whole exome sequencing (WES) may be considered when panel testing is negative but clinical suspicion remains high 8
• Avoid routine whole-genome or exome sequencing in hEDS, as no causative genes have been identified 4, 1

Essential Screening Labs Before Genetic Testing

Baseline Metabolic Assessment

• Complete blood count (CBC) with differential to evaluate for cytopenias or eosinophilia that may suggest systemic involvement 9
• Comprehensive metabolic panel including liver and renal function 9
• Lactate dehydrogenase (LDH) as a marker for tissue breakdown or hemolysis 9

Autoimmune and Inflammatory Markers

• Antinuclear antibody (ANA) and antineutrophil cytoplasmic antibodies (ANCA) if systemic arteriopathy is suspected 6
• Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for inflammatory assessment 6
• Quantitative immunoglobulin levels including IgE if allergic or mast cell symptoms present 6

Critical Imaging Studies (Not Labs, But Essential)

• Echocardiogram to evaluate for aortic root dilation, present in 25-33% of classic and hypermobile EDS 1
• MR angiography of head, neck, thorax, abdomen, and pelvis for suspected vascular EDS or Loeys-Dietz syndrome to assess arterial tortuosity and aneurysms 10

Common Diagnostic Pitfalls

The most dangerous error is failing to recognize vascular EDS, which carries high mortality risk from arterial or organ rupture. 1, 5

• Never perform invasive diagnostic procedures (including skin biopsy for fibroblast culture) in suspected vascular EDS without extreme caution, as these can precipitate fatal complications 1, 5
• Do not routinely test for MCAS in all hEDS patients with isolated GI symptoms—reserve tryptase testing for those with multisystem symptoms suggesting generalized mast cell disorder 1
• Genetic testing may fail even when protein analysis confirms a collagen defect, as only coding sequences are investigated and each family typically has its own specific mutation 1
• Avoid using symptom codes when specific joint dysfunction codes are more appropriate for documentation purposes 11

When to Refer for Formal Genetics Consultation

Refer to medical genetics specialists when clinical features suggest EDS, family history shows autosomal dominant inheritance, or when arteriopathy is suspected. 4, 1

• Genetic counseling is paramount before mutation screening due to complex financial, insurance, familial, and social implications 4
• Medical genetics consultation should be performed at referral centers with experience in genetically mediated arteriopathies 4
• Three-generation pedigree assessment helps identify inheritance patterns and guide testing strategy 4